O	0	3	The
O	4	7	use
O	8	10	of
B-intervention	11	19	Ligasure
I-intervention	20	26	vessel
I-intervention	27	34	sealing
I-intervention	35	41	system
O	42	44	in
O	45	53	axillary
O	54	64	dissection
O	64	65	;
O	66	72	effect
O	73	75	on
B-condition	76	82	seroma
I-condition	83	92	formation
O	92	93	.

O	94	100	Seroma
O	101	110	formation
O	111	113	is
O	114	117	the
O	118	122	most
O	123	131	frequent
O	132	145	postoperative
O	146	158	complication
O	159	164	after
O	165	173	axillary
O	174	184	dissection
O	185	188	for
O	189	195	breast
O	196	203	surgery
O	204	208	with
O	209	211	an
O	212	221	incidence
O	222	224	of
O	225	227	10
O	228	229	-
O	230	232	50
O	233	234	%
O	234	235	.

O	236	240	This
O	241	252	prospective
O	253	261	clinical
O	262	272	randomized
O	273	278	study
O	279	282	was
O	283	290	carried
O	291	294	out
O	295	297	to
O	298	306	evaluate
O	307	310	the
O	311	319	Ligasure
O	320	326	vessel
O	327	334	sealing
O	335	341	system
O	342	345	and
O	346	349	its
O	350	356	effect
O	357	359	on
O	360	375	seromaformation
O	376	379	and
O	380	385	other
O	386	399	complications
O	400	403	for
O	404	412	axillary
O	413	423	dissection
O	423	424	.

O	425	432	Between
O	433	440	January
O	441	445	2006
O	446	449	and
O	450	458	November
O	459	463	2007
O	463	464	,
O	465	468	the
O	469	477	patients
O	478	482	with
O	483	500	histopathological
O	501	510	diagnosis
O	511	513	of
O	514	520	breast
O	521	527	cancer
O	528	532	were
O	533	541	analysed
O	542	555	prospectively
O	555	556	.

O	557	560	The
B-eligibility	561	569	patients
I-eligibility	570	574	with
I-eligibility	575	583	positive
I-eligibility	584	592	sentinel
I-eligibility	593	598	lymph
I-eligibility	599	603	node
I-eligibility	604	610	biopsy
I-eligibility	611	613	or
I-eligibility	614	622	clinical
I-eligibility	623	631	axillary
I-eligibility	632	643	involvement
O	644	648	were
O	649	657	included
O	658	660	in
O	661	664	the
O	665	670	study
O	670	671	,
O	672	675	and
O	676	679	the
O	680	688	patients
O	689	692	who
O	693	702	underwent
O	703	714	neoadjuvant
O	715	722	therapy
O	723	725	or
O	726	731	using
O	732	746	anticoagulants
O	747	751	have
O	752	756	been
O	757	765	excluded
O	766	770	from
O	771	774	the
O	775	780	study
O	780	781	.

O	782	790	Patients
O	791	795	were
O	796	803	divided
O	804	808	into
O	809	812	two
O	813	818	study
O	819	825	groups
O	825	826	.

O	827	835	Axillary
O	836	846	dissection
O	847	850	was
O	851	860	performed
O	861	863	in
O	864	867	the
O	868	873	first
O	874	879	group
O	880	882	by
O	883	891	LigaSure
O	892	895	and
O	896	898	in
O	899	902	the
O	903	909	second
O	910	915	group
O	916	918	by
B-control	919	926	linking
I-control	927	930	and
I-control	931	945	electrocautery
O	945	946	.

O	947	952	There
O	953	957	were
O	958	959	a
O	960	965	total
O	966	968	of
B-total-participants	969	975	thirty
I-total-participants	976	981	three
O	982	990	patients
O	991	995	with
O	996	997	a
O	998	1002	mean
O	1003	1006	age
O	1007	1009	of
B-age	1010	1012	51
I-age	1012	1013	.
I-age	1013	1014	4
I-age	1015	1016	+
I-age	1016	1017	-
I-age	1018	1020	13
I-age	1020	1021	.
I-age	1021	1022	7
O	1022	1023	.

O	1024	1026	In
O	1027	1032	group
O	1033	1036	one
O	1036	1037	,
O	1038	1042	mean
O	1043	1046	age
O	1047	1049	of
O	1050	1058	patients
O	1059	1062	was
O	1063	1065	54
O	1065	1066	.
O	1066	1067	1
O	1068	1069	+
O	1069	1070	-
O	1071	1073	13
O	1073	1074	.
O	1074	1075	2
O	1076	1079	and
O	1080	1082	48
O	1082	1083	.
O	1083	1085	68
O	1086	1087	+
O	1087	1088	-
O	1089	1091	14
O	1091	1092	.
O	1092	1093	1
O	1094	1096	in
O	1097	1102	group
O	1103	1106	two
O	1106	1107	.

O	1108	1113	There
O	1114	1117	was
O	1118	1120	no
O	1121	1132	significant
O	1133	1144	statistical
O	1145	1155	difference
O	1156	1163	between
O	1164	1167	the
O	1168	1174	groups
O	1175	1184	regarding
O	1185	1188	age
O	1188	1189	,
O	1190	1194	body
O	1195	1199	mass
O	1200	1205	index
O	1205	1206	,
O	1207	1214	excised
O	1215	1221	tissue
O	1222	1228	weight
O	1228	1229	,
O	1229	1235	tumour
O	1236	1240	size
O	1241	1244	and
O	1245	1251	number
O	1252	1254	of
O	1255	1262	excised
O	1263	1268	lymph
O	1269	1274	nodes
O	1274	1275	.

O	1276	1279	The
O	1280	1283	use
O	1284	1286	of
O	1287	1295	Ligasure
O	1296	1303	reduced
B-outcome	1304	1312	drainage
I-outcome	1313	1319	amount
O	1320	1323	and
B-outcome	1324	1332	duration
I-outcome	1333	1335	of
I-outcome	1336	1341	drain
O	1342	1346	till
O	1347	1354	removal
O	1354	1355	,
O	1356	1359	but
O	1360	1369	increased
B-outcome	1370	1379	operative
I-outcome	1380	1384	time
O	1384	1385	.

O	1386	1391	There
O	1392	1396	were
O	1397	1399	no
O	1400	1411	significant
O	1412	1423	differences
O	1424	1431	between
O	1432	1437	study
O	1438	1444	groups
O	1445	1454	regarding
O	1455	1458	the
B-outcome	1459	1472	complications
O	1472	1473	.

O	1474	1482	LigaSure
O	1483	1497	electrothermal
O	1498	1505	bipolar
O	1506	1512	vessel
O	1513	1520	sealing
O	1521	1527	system
O	1528	1531	can
O	1532	1534	be
O	1535	1541	safely
O	1542	1546	used
O	1547	1549	in
O	1550	1558	axillary
O	1559	1569	dissection
O	1570	1572	as
O	1573	1575	an
O	1576	1587	alternative
O	1588	1590	to
O	1591	1602	traditional
O	1603	1610	methods
O	1610	1611	.
